Latest News

STAT Plus: Large employers could have saved money if more biosimilars had been prescribed

If some of the largest U.S. employers had used biosimilar versions of a pair of widely used brand-name biologic medicines two years ago, they could have saved an average of $1.5 million and their employees would also have spent hundreds of dollars less, according to a new study.

Nearly all of the savings would have been realized if those 13 companies had relied on biosimilar versions of Remicade, a popular treatment for rheumatoid arthritis and Crohn’s disease, among other ailments. The savings, meanwhile, from biosimilar versions of Neupogen, a bone marrow stimulant for cancer patients, would have amounted to less than $18,000, on average. Spending on the two drugs represented up to 2.7% of typical annual spending on pharmaceuticals by the companies.

Continue to STAT Plus to read the full story…

Source link

Related posts

Medical News Today: What to know about acute respiratory failure


日本厚生勞動省核准Invivoscribe的LeukoStrat CDx FLT3突變檢測作為第一三共Quizartinib的搭配診斷試劑,用於治療復發/難治型FLT3-ITD AML。擴大用途包括EDTA中採集的樣本


STAT Plus: A CAR-T bottleneck: Centers that collect patient cells feel crunch from growing demand


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy